Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Prime Medicine (PRME) Income from Continuing Operations: 2021-2025

Historic Income from Continuing Operations for Prime Medicine (PRME) over the last 4 years, with Sep 2025 value amounting to -$52.8 million.

  • Prime Medicine's Income from Continuing Operations fell 0.60% to -$52.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$199.6 million, marking a year-over-year increase of 8.97%. This contributed to the annual value of -$195.9 million for FY2024, which is 1.14% up from last year.
  • As of Q3 2025, Prime Medicine's Income from Continuing Operations stood at -$52.8 million, which was down 0.46% from -$52.6 million recorded in Q2 2025.
  • In the past 5 years, Prime Medicine's Income from Continuing Operations ranged from a high of -$16.4 million in Q3 2021 and a low of -$65.6 million during Q4 2023.
  • For the 3-year period, Prime Medicine's Income from Continuing Operations averaged around -$50.1 million, with its median value being -$51.9 million (2025).
  • Over the last 5 years, Prime Medicine's Income from Continuing Operations had its largest YoY gain of 37.54% in 2022, and its largest YoY loss of 78.83% in 2022.
  • Quarterly analysis of 5 years shows Prime Medicine's Income from Continuing Operations stood at -$62.9 million in 2021, then soared by 37.54% to -$39.3 million in 2022, then plummeted by 67.10% to -$65.6 million in 2023, then surged by 35.60% to -$42.3 million in 2024, then declined by 0.60% to -$52.8 million in 2025.
  • Its last three reported values are -$52.8 million in Q3 2025, -$52.6 million for Q2 2025, and -$51.9 million during Q1 2025.